首页> 外文期刊>Acta Cardiologica >Comparison of intracoronary adenosine and isosorbide dinitrate on no-reflow/slow flow during rotational atherectomy.
【24h】

Comparison of intracoronary adenosine and isosorbide dinitrate on no-reflow/slow flow during rotational atherectomy.

机译:冠状动脉内腺苷和硝酸异山梨酯在旋切术中无复流/慢流的比较。

获取原文
获取原文并翻译 | 示例
       

摘要

OBJECTIVE: To compare the effect of intracoronary adenosine and isosorbide dinitrate (ISDN) on no-reflow/slow flow during high-speed rotational atherectomy (HSRA) in patients with complex coronary artery disease (CAD). METHODS AND RESULTS: Medical records from consecutive patients diagnosed with complex CAD between November 2002 and March 2006 who underwent HSRA at the Tri-Service General Hospital, National Defence Medical Centre in Taipei, Taiwan, were included in this study. Patients in the adenosine group (n=32) received a 50 microg intracoronary adenosine bolus prior to the initiation of burr rotation and during each ablation. Patients in the ISDN group (n=58) received a 0.5 mg intracoronary ISDN bolus at comparable time points. Angiographic success was achieved in 100% of patients in the adenosine group and 98.3% (57/58) in the ISDN group.The procedural success rates were 96.9% (31/32) in the adenosine group and 89.7% (52/58) in the ISDN group. One patient (3.1%) from the adenosine group and six patients (10.3%) from the ISDN group experienced no-reflow/slow flow (P = 0.414). No in-hospital mortality occurred and target vessel revascularization was unnecessary. CONCLUSIONS: Intracoronary administration of either adenosine or ISDN during HSRA appears safe and administration of either agent may be effective in decreasing the incidence of no-reflow/slow flow during HSRA. Further large, prospective, randomized, placebo-controlled trials are required.
机译:目的:比较冠状动脉内腺苷和硝酸异山梨酯(ISDN)对复杂冠状动脉疾病(CAD)患者高速旋磨术(HSRA)期间无复流/慢血流的影响。方法和结果:本研究包括2002年11月至2006年3月在台湾台北国防医学中心三军总医院接受HSRA确诊的患有复杂CAD的连续患者的病历。腺苷组(n = 32)的患者在毛刺旋转开始之前和每次消融期间接受了50微克冠状动脉内腺苷推注。 ISDN组(n = 58)的患者在相近的时间点接受了0.5 mg冠状动脉ISDN推注。腺苷组的血管造影成功率为100%,而ISDN组的血管造影成功率为98.3%(57/58)。腺苷组的手术成功率为96.9%(31/32),程序成功率为89.7%(52/58)在ISDN组中。腺苷组的1例患者(3.1%)和ISDN组的6例患者(10.3%)经历了无复流/慢流(P = 0.414)。没有发生院内死亡,并且不需要靶血管血运重建。结论:在HSRA期间冠状动脉内给予腺苷或ISDN似乎是安全的,并且任何一种药物的给药均可能有效降低HSRA期间无复流/慢流的发生率。需要进一步的大型,前瞻性,随机,安慰剂对照试验。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号